Cytokinetics inc (CYTK)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenues:
Research and development, milestone, grant and other revenues, net

-

-

-

44,236

14,740

17,566

7,547

3,382

1,946

1,090

-

Total revenues

26,868

31,501

13,368

-

-

-

-

-

-

-

-

Research and development revenues from related parties, net

-

-

-

-

-

19,538

2,019

4,177

2,054

1,487

7,171

License revenues from related parties

-

-

-

-

-

0

17,230

0

-

-

74,367

Total revenues

-

-

-

106,407

28,658

46,940

30,648

7,559

4,000

2,577

81,538

Operating expenses:
Research and development

86,125

89,135

90,296

59,897

46,398

44,426

49,450

35,643

37,182

38,013

39,840

General and administrative

39,610

31,282

36,468

27,823

19,667

17,268

15,092

12,429

13,590

14,199

15,626

Total operating expenses

125,735

120,417

126,764

87,720

66,065

61,694

64,542

48,016

51,964

52,212

55,443

Restructuring reversals

-

-

-

-

-

-

-

-56

1,192

-

-23

Operating loss

-98,867

-88,916

-113,396

18,687

-37,407

-14,754

-33,894

-40,457

-47,964

-49,635

26,095

Interest expense

6,623

3,797

3,016

2,698

268

0

-

-

-

-

-

Non-cash interest expense on liability related to the sale of future royalties

20,737

17,767

13,980

0

0

-

-

-

-

-

-

Interest and other income, net

4,535

4,191

2,602

464

174

108

177

87

104

172

-1,401

Net (loss) income before income taxes

-

-

-

-

-

-14,646

-33,717

-40,370

-47,860

-49,463

24,694

Income tax benefit

-

-

-

-

-

0

0

0

0

-176

150

Net loss

-121,692

-106,289

-127,790

16,453

-37,501

-14,646

-33,717

-40,370

-47,860

-49,287

24,544

Net (loss) income per share basic

-

-

-

0.41

-0.97

-0.41

-

-

-

-

0.43

Net (loss) income per share diluted

-

-

-

0.39

-0.97

-0.41

-

-

-

-

0.42

Weighted-average number of shares used in computing net (loss) income per share basic

-

-

-

39,943

38,814

35,709

-

-

-

-

57,390

Weighted-average number of shares used in computing net (loss) income per share diluted

-

-

-

42,561

38,814

35,709

-

-

-

-

57,961

Deemed dividend related to beneficial conversion feature of convertible preferred stock

-

-

-

-

-

-

-

1,307

2,857

-

-

Net loss allocable to common stockholders

-

-

-

-

-

-

-

-41,677

-50,717

-49,287

24,544

Net loss per share — basic and diluted

-2.11

-1.95

-2.59

-

-

-

-1.24

-2.30

-4.30

-0.77

-

Weighted-average number of shares used in computing net loss per share — basic and diluted

57,575

54,420

49,404

-

-

-

27,275

18,107

11,800

64,165

-

Other comprehensive income:
Unrealized gain on available-for-sale securities, net

179

157

206

-12

153

-11

-11

15

-

-

-

Change in unrealized gain (loss) on investments

-

-

-

-

-

-

-

-

-

-5

-

Comprehensive loss

-121,513

-106,132

-127,584

16,441

-37,348

-14,657

-33,728

-40,355

-47,853

-49,292

-

Research and Development Revenues [Member]
Total revenues

26,868

26,368

-

-

-

-

-

-

-

-

-

Research and Development, Grant and Other Revenues, Net [Member]
Total revenues

-

-

4,569

-

-

-

-

-

-

-

-

License Revenues [Member]
Total revenues

0

5,133

8,799

62,171

13,918

9,836

3,852

0

-

-

-